Brian Aldana

Biostatistician
M_MED-ZSFG-PULM

Publications

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.

The Journal of antimicrobial chemotherapy

Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.

The Lancet. Infectious diseases

Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, Sebe M, Rassool M, Wallis RS, Ntinginya N, Liyoyo A, Mbeya B, Wagnerberger L, Zumba T, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut JA, Aarnoutse R, McHugh TD, Wildner L, Boeree MJ, Geiter L, Cho YL, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

The Lancet. Infectious diseases

Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, Wallis RS, Ntinginya N, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Stoycheva K, Zumba T, Noreña I, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut J, Aarnoutse RE, McHugh TD, Wildner L, Boeree M, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, PanACEA consortium